|
|
|
|
|
21.04.26 - 17:48
|
Roche′s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD (GlobeNewswire EN)
|
|
|
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint. The primary endpoint was measured by the time from randomisation to the first MOGAD relapse during the double-blind treatment period (p=0.0025). The results were shared today at a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago....
|
|
|
|
|
|
|
|
|
|
|
21.04.26 - 07:03
|
FDA accepts application for Roche′s Gazyva/Gazyvaro for the treatment of the most common form of lupus (GlobeNewswire EN)
|
|
|
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of systemic lupus erythematosus (SLE). The filing acceptance is based on positive results from the phase III ALLEGORY study, which demonstrated a statistically significant and clinically meaningful benefit in the primary endpoint of SLE Responder Index 4 (SRI-4) at 52 weeks – a measure that assesses changes in disease severity, symptoms and physical condition.2 The FDA is expected to make a decision on an approval by December 2026. Gazyva/Gazyvaro is already approved for adults with lupus nephritis in the US and EU....
|
|
|
|
|
|
|
|
|
17.04.26 - 17:18
|
LA ROCHE-POSAY SPONSORS JANNIK SINNER...′S SHADOW (PR Newswire)
|
|
|
The dermatological skincare brand reframes the importance of sun protection through a new kind of sponsorship with "Shadow Sponsor", a culturally provocative idea PARIS, April 17, 2026 /PRNewswire/ -- In sports, athletes compete amidst a sea of logos. Sponsorship is everywhere. Logos......
|
|
|
|
|
16.04.26 - 15:30
|
Sciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of Roche (Cision)
|
|
|
Sciety portfolio company Saga Diagnostics has entered into an agreement to be acquired by Foundation Medicine, Inc., a global precision medicine company and an independent subsidiary of Roche, for a deal value of up to USD 595 million, including commercial and regulatory milestone payments.
[image]
Saga Diagnostics is a biotechnology company developing advanced diagnostic methods to detect and monitor cancer after treatment. The company's technology is based on the analysis of tumour-specific structural variations in DNA from blood samples, in contrast to more traditional methods that...
|
|
|
16.04.26 - 14:36
|
Moog Inc. to Announce Second Quarter Fiscal 2026 Earnings on April 24, 2026 (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B) will release its second quarter fiscal 2026 earnings on Friday, April 24, 2026. In conjunction with this release, Pat Roche, CEO, and Jennifer Walter, CFO, will host a conference call beginning at 10:00 a.m. ET, which will be simultaneously broadcast live online.
Listeners can access the conference call live or in replay mode at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the company's website, and the call replay will remain archived for 45 days.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com. Co...
|
|
|
|
|
16.04.26 - 13:42
|
Roche übernimmt Saga Diagnostics (Cash)
|
|
|
Pharma - Für maximal 595 Millionen US-Dollar übernimmt Roche die amerikanische Saga Diagnostics inklusive deren Testplattform «Pathlight»....
|
|
|
|
|
16.04.26 - 12:36
|
Roche startet neue Phase-III-Studie mit Gentherapie Elevidys (Cash)
|
|
|
- Der Pharmakonzern Roche kündigt eine neue Phase-III-Studie für die Gentherapie Elevidys (Delandistrogene Moxeparvovec) an. Ziel ist es, den Zugang für Jungen mit der Krankheit Duchenne-Muskeldystrophie (DMD) in Europa und weiteren Regionen zu erweitern....
|
|
|
14.04.26 - 15:06
|
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs (Business Wire)
|
|
|
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey.
Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across multiple therapeutic modalities. Prior to joining Kashiv, he spent over a decade in international leadership roles across Singapore, China, and Switzerland with leading global organizations including Genentech, Roche, Merck Group, and Bayer Corp. He holds a Bachelor of Science in Pharmacy from Saint Joseph's University and has completed his Global Leadership Management program from INSEAD / Stanford University. As COO, Viet will oversee manufacturing, quality, supply chain, and engineering across global operation...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
